Sermorelin

Also known as GRF 1-29.

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification: GHRH (1–29) analogue
Approval status: Research only · Not approved for human use
Research status: Investigational / reference listing.
Molecular formula: Insufficient reliable evidence identified.
Molecular weight: Insufficient reliable evidence identified.
Sequence: GHRH fragment 1–29.
Primary biological target: Insufficient reliable evidence identified.
Half-life: Insufficient reliable evidence identified.
Routes investigated: Insufficient reliable evidence identified.
Human evidence level: D — Primarily animal / preclinical evidence

What is it?

Formerly used diagnostically/therapeutically in some settings; not a current consumer anti-ageing medicine here. Not sold.

Mechanism of action

GHRH receptor agonism.

GH pulse stimulation if bioactive.

What is it being studied for?

GH deficiency diagnostics historically

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: D · Primarily animal / preclinical evidence

Human research

Historical clinical use; not a licence to grey-market compound.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

GHRH fragment pharmacology.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

GH-axis effects.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for unapproved use.

Regulatory status

Not offered as a consumer peptide.

Educational only.

Citations

[1] Encyclopaedia note
Encyclopaedia note

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Healthy Ageing · Compare peptides